2024/02/02 16:10:22 | |
---|---|
Price | |
8.313 EUR | |
Difference | 8.92% (0.68) |
ISIN | NL00150002Q7 |
Symbol | VVY |
Exchange | London Stock Exchange |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 21 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 8.313 EUR |
High | 8.313 EUR |
Low | 8.313 EUR |
Close (prev. day) | 7.6321 EUR |
VWAP | 8.313 EUR |
Volume (pcs) | 3,000 |
Trading volume | 24,939.00 |
Number of trades | 1 |
Last size | 3,000 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/04/26 | Global Equity Ratings | ||
2024/04/03 | Global Equity Ratings | ||
2024/03/13 | Global Equity Ratings | ||
2024/02/22 | Global Equity Ratings | ||
2024/02/14 | Global Equity Ratings |
2024/02/02 16:10:22 | |
---|---|
Price | |
8.313 EUR | |
Difference | 8.92% (0.68) |
ISIN | NL00150002Q7 |
Symbol | VVY |
Exchange | London Stock Exchange |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 21 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 8.313 EUR |
High | 8.313 EUR |
Low | 8.313 EUR |
Close (prev. day) | 7.6321 EUR |
VWAP | 8.313 EUR |
Volume (pcs) | 3,000 |
Trading volume | 24,939.00 |
Number of trades | 1 |
Last size | 3,000 |
6m | 1Y | 3Y | |
Perf (%) | - | - | - |
Perf (abs.) | - | - | - |
Beta | 3.54 | 2.12 | 1.23 |
Volatility | - | - | 73.45 |
Ø price 5 days | Ø volume 5 days (pcs.) | - EUR (-) |
Ø price 30 days | Ø volume 30 days (pcs.) | - EUR (-) |
Ø price 100 days | Ø volume 100 days (pcs.) | 7.973 EUR (175) |
Ø price 250 days | Ø volume 250 days (pcs.) | 7.973 EUR (72) |
YTD High | date | 8.313 EUR (2024/02/02) |
YTD Low | date | 8.313 EUR (2024/02/02) |
52 Weeks High | date | 8.313 EUR (2024/02/02) |
52 Weeks Low | date | 7.632 EUR (2023/12/05) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/05/10 | 16:57 | 0.784 EUR | 0.02 | 18 |
Stuttgart | 2024/05/10 | 10:30 | 0.778 EUR | 0.00 | 4 |
Munich | 2024/05/10 | 08:15 | 0.822 EUR | 0.00 | 1 |
London Stock Exchange | 2024/02/02 | 16:10 | 8.313 EUR | 0.02 | 1 |
Frankfurt | 2024/05/10 | 15:13 | 0.80 EUR | 0.00 | 2 |
Euronext Amsterdam | 2024/05/10 | 17:35 | 0.795 EUR | 0.28 | 247 |
Duesseldorf | 2024/05/10 | 08:11 | 0.799 EUR | 0.00 | 1 |
Berlin | 2024/05/10 | 21:50 | 0.795 EUR | 0.00 | 17 |
VIVORYON THERAPEUTICS NV |
- - |
Weinbergweg 22 - 06120 Halle |
Telefon: +49-345-555-99-00 |
Fax: + |
E-mail: info@vivoryon.com |
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany. |
Frank Weber | Chairman of Managing Board |
Michael Schaeffer | Member of Executive Committee |
Anne Doering | Member of Executive Committee |
Florian Schmid | Member of Executive Committee |
Erich Maximilian Platzer | Chairman of Supervisory Board |
Claudia Riedl | Member of Supervisory Board |
Michael Schaeffer | Member of Supervisory Board |
Samir Shah | Member of Supervisory Board |
Anne Doering | Member of Supervisory Board |
Charlotte Lohmann | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer